JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-26-34
L.A. Romodin1, E.I. Yashkina1, A.A. Moskovskij2
Fluorimetric Evaluation of the Effect of Riboxin, Copper Chlorophyllin, Trolox and the Soluble form of Indralin on the Growth Properties of A549 Cells in Culture
1 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
2 Russian Biotechnological University, Moscow, Russia
Contact person: L.A. Romodin, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Currently, cell cultures are most often used as an experimental model system in biological research. However, to correctly plan studies using this model system, many aspects must be taken into account. Thus, to be able to correctly assess the effect of radioprotective drugs on cells, it is first necessary to study the effect of these substances on the properties of cells in culture. And the main property for work using plate readers is the ability of cells to adhere to the bottom of the plate and the rate of cell proliferation. This work is devoted to the study of human riboxin (inosine), copper chlorophyllin, trolox and indralin, the growth properties of cells in a culture based on the A549 cell line - human lung adenocarcinoma. Riboxin, chlorophyllin and trolox are promising compounds that make it possible to study their radioprotective properties. Indralin is a reference classic radioprotector. This process used a water-soluble form containing tartaric acid to allow indralin to dissolve in water. The experiment consisted of incubating A549 cells for 24 hours in a solution of riboxin (inosine), copper chlorophyllin, Trolox or tartaric acid at a concentration of 2 mM or in a mixture of 2 mM tartaric acid and 1.9 mM indralin, followed by assessment of the cell content in the samples compared to cells incubated without the addition of these substances, based on the fluorescence of the Hoechst-33342 dye. An additional experiment with chlorophyllin consisted in incubating cells with chlorophyllin already attached to the bottom of the tablet in the concentration range of 50–500 μM for 2.5 hours, followed by an assessment of the content of the remaining cells in the tablet. All studied substances statistically significantly reduced the cell content in the samples compared to the control. The greatest decrease in cell content was observed in the sample with chlorophyllin, and the least – with riboxin. As a result of additional experience in incubating already attached cells in chlorophyllin solution with concentrations of 50–500 μM, it was shown that this substance dose-dependently inhibits the adhesive properties of cells of the A549 line. At the same time, chlorophyllin already at a concentration of 50 μM statistically significantly reduced the cell content in the sample after washing the wells of the tablet compared with the control sample.
The decrease in cell content in the sample containing a mixture of indralin and tartaric acid was statistically significantly more pronounced than that caused by incubation in a solution of tartaric acid alone. That is, the recognized radioprotector indralin demonstrated a pronounced inhibition of the growth properties of the A549 cell line. Based on the information obtained, we can conclude that when planning future studies of the substances studied in this work on a cell culture model, it is necessary to take into account the fact that they inhibit the growth of the cell culture.
Keywords: cell culture, A549, riboxin, copper chlorophyllin, trolox, indralin, tartaric acid, influence estimation
For citation: Romodin LA, Yashkina EI, Moskovskij AA. Fluorimetric Evaluation of the Effect of Riboxin, Copper Chlorophyllin, Trolox and the Soluble form of Indralin on the Growth Properties of A549 Cells in Culture. Medical Radiology and Radiation Safety. 2024;69(3):26–34. (In Russian). DOI:10.33266/1024-6177-2024-69-3-26-34
References
1. Lei G., Zhang Y., Koppula P., Liu X., Zhang J., Lin S.H., Ajani J.A., Xiao Q., Liao Z., Wang H., Gan B. The Role of Ferroptosis in Ionizing Radiation-Induced Cell Death and Tumor Suppression. Cell Research. 2020;30:146–162. doi: 10.1038/s41422-019-0263-3.
2. Raitanen J., Barta B., Hacker M., Georg D., Balber T., Mitterhauser M. Comparison of Radiation Response between 2D and 3D Cell Culture Models of Different Human Cancer Cell Lines. Cells. 2023;12;3:360. doi: 10.3390/cells12030360.
3. Jooyan N., Mortazavi S.M.J., Goliaei B., Faraji-Dana R. Indirect Effects of Interference of Two Emerging Environmental Contaminants on Cell Health: Radiofrequency Radiation and Gold Nanoparticles. Chemosphere. 2024;349:140942. doi: 10.1016/j.chemosphere.2023.140942.
4. Pustovalova M., Astrelina capital Te C., Grekhova A., Vorobyeva N., Tsvetkova A., Blokhina T., Nikitina V., Suchkova Y., Usupzhanova D., Brunchukov V., Kobzeva I., Karaseva capital Te C., Ozerov I.V., Samoylov A., Bushmanov A., Leonov S., Izumchenko E., Zhavoronkov A., Klokov D., Osipov A.N. Residual GammaH2AX Foci Induced by Low Dose X-Ray Radiation in Bone Marrow Mesenchymal Stem Cells Do Not Cause Accelerated Senescence in the Progeny of Irradiated Cells. Aging. 2017;9;11:2397–2410. doi: 10.18632/aging.101327.
5. Romodin L.A., Yashkina E.I., Moskovskiy A.A. Fluorimetric Evaluation of the Effect of Malic, Succinic and Ascorbic Acids on the Growth Properties of A549 Cells in Culture. Medical Radiology and Radiation Safety. 2024;69;1:28–32 (In Russ.). doi: 10.33266/1024-6177-2024-69-1-28-32.
6. Sycheva L.P., Rozhdestvenskiy L.M., Lisina N.I., Shlyakova T.G., Zorin V.V. Antimutagenic Activity and Hepatoprotective Effect of Anti-Radiation Drugs. Medical Genetics. 2020;19;9(218):81–82 (In Russ.). doi: 10.25557/2073-7998.2020.09.81-82.
7. Sycheva L.P., Lisina N.I., Shchegoleva R.A., Rozhdestvenskiy L.M. Antimutagenic Effect of Anti-Radiation Drugs in an Experiment on Mice. Radiacionnaya Biologiya. Radioekologiya. 2019;59;4:388–393. (In Russ.). doi: 10.1134/S086980311904012X.
8. Gudkov S.V., Gudkova O.Yu., Shtarkman I.N., Gapeev A.B., Chemeris N.K., Bruskov V.I. Guanosine and Inosine as Natural Geneprotectors for Mice Blood Cells Expo Sed to X-rays. Radiacionnaya Biologiya. Radioekologiya. 2006;46;6:713–718 (In Russ.).
9. Popova N.R., Gudkov S.V., Bruskov V.I. Natural Purine Compounds as Radioprotective Agents. Radiacionnaya Biologiya. Radioekologiya. 2014;54;1:38–49 (In Russ.). doi: 10.7868/S0869803114010135.
10. Hou B., Xu Z.W., Yang C.W., Gao Y., Zhao S.F., Zhang C.G. Protective Effects of Inosine on Mice Subjected to Lethal Total-Body Ionizing Irradiation. Journal of Radiation Research. 2007;48;1:57–62. doi: 10.1269/jrr.06067.
11. Blanco J.M., Caamano O., Fernandez F., Rodriguez-Borges J.E., Balzarini J., de Clercq E. Carbocyclic Analogues of Nucleosides from bis-(Hydroxymethyl)-Cyclopentane: Synthesis, Antiviral and Cytostatic Activities of Adenosine, Inosine and Uridine Analogues. Chemical & Pharmaceutical Bulletin. 2003;51;9:1060–1063. doi: 10.1248/cpb.51.1060.
12. Zerniy E.Yu., Golovastova M.O., Baksheeva V.E., Kabanova E.I., Ishutina I.E., Gancharova O.S., Gusev A.E., Savchenko M.S., Loboda A.P., Sotnikova L.F., Zamyatnin A.A., Philippov P.P., Senin I.I. Alterations in Tear Biochemistry Associated with Chronic Dry Eye Syndrome in Postanesthetic Period. Biohimiya. 2017;82;1:137–148. (In Russ.).
13. McClain D.E., Kalinich J.F., Ramakrishnan N. Trolox Inhibits Apoptosis in Irradiated MOLT-4 Lymphocytes. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 1995;9;13:1345–1354. doi: 10.1096/fasebj.9.13.7557025.
14. Jiang S.J., Xiao X., Li J., Mu Y. Lycium Barbarum Polysaccharide-Glycoprotein Ameliorates Ionizing Radiation-Induced Epithelial Injury by Regulating Oxidative Stress and Ferroptosis Via the Nrf2 Pathway. Free Radical Biology & Medicine. 2023;204:84–94. doi: 10.1016/j.freeradbiomed.2023.04.020.
15. Sangsuwan T., Pour Khavari A., Blomberg E., Romell T., Godoy P., Harms-Ringdahl M., Haghdoost S. Oxidative Stress Levels and DNA Repair Kinetics in Senescent Primary Human Fibroblasts Exposed to Chronic Low Dose Rate of Ionizing Radiation. Frontiers in Bioscience. 2023;28;11:296. doi: 10.31083/j.fbl2811296.
16. Ding S.S., Sun P., Zhang Z., Liu X., Tian H., Huo Y.W., Wang L.R., Han Y., Xing J.P. Moderate Dose of Trolox Preventing the Deleterious Effects of Wi-Fi Radiation on Spermatozoa In vitro through Reduction of Oxidative Stress Damage. Chinese Medical Journal. 2018;131;4:402–412. doi: 10.4103/0366-6999.225045.
17. Zakharova O.D., Frolova T.S., Yushkova Y.V., Chernyak E.I., Pokrovskiy A.G., Pokrovskiy M.A., Morozov S.V., Sinitsina O.I., Grigor’ev I.A., Nevinskiy G.A. Antioxidant and Antitumor Activity of Trolox, Trolox Succinate, and Alpha-Tocopheryl Succinate Conjugates with Nitroxides. European Journal of Medicinal Chemistry. 2016;122:127–137. doi: 10.1016/j.ejmech.2016.05.051.
18. Pozdeev A.V., Lysenko N.P. Increasing the Radiation Resistance of the Mammalian Body when Using Chlorophyll Preparations in Conditions of Radioactive Environmental Pollution. Izvestiya Mezhdunarodnoy Akademii Agrarnogo Obrazovaniya. 2018;42;2:60–62 (In Russ.).
19. Pozdeev A.V., Gugalo V.P. The Effect of Chlorophyll Preparation on the Content of Malondialdehyde in Radiation Pathology. Bulletin of the Kursk State Agricultural Academy. 2012;2:107–109 (In Russ.).
20. Kumar S.S., Shankar B., Sainis K.B. Effect of Chlorophyllin against Oxidative Stress in Splenic Lymphocytes in Vitro and in Vivo. Biochimica et Biophysica Acta. 2004;1672;2:100–111. doi: 10.1016/j.bbagen.2004.03.002.
21. Geric M., Gajski G., Mihaljevic B., Miljanic S., Domijan A.M., Garaj-Vrhovac V. Radioprotective Properties of Food Colorant Sodium Copper Chlorophyllin on Human Peripheral Blood Cells in Vitro. Mutation Research. Genetic Toxicology and Environmental Mutagenesis. 2019;845:403027. doi: 10.1016/j.mrgentox.2019.02.008.
22. Morales-Ramirez P., Mendiola-Cruz M.T. In vivo Radioprotective Effect of Chlorophyllin on Sister Chromatid Exchange Induction in Murine Spermatogonial Cells. Mutation Research. 1995;344;1-2:73–78. doi: 10.1016/0165-1218(95)90041-1.
23. Morales-Ramirez P., Garcia-Rodriguez M.C. In vivo Effect Of Chlorophyllin On Gamma-Ray-Induced Sister Chromatid Exchange in Murine Bone Marrow Cells. Mutation Research. 1994;320;4:329–334. doi: 10.1016/0165-1218(94)90085-x.
24. Abraham S.K., Sarma L., Kesavan P.C. Role of Chlorophyllin as an in Vivo Anticlastogen: Protection Against Gamma-Radiation and Chemical Clastogens. Mutation Research. 1994. Vol. 322, № 3. – P.: 209–212. doi: 10.1016/0165-1218(94)90008-6.
25. Zimmering S., Olvera O., Hernandez M.E., Cruces M.P., Arceo C., Pimental E. Evidence for a Radioprotective Effect of Chlorophyllin in Drosophila. Mutation Research. 1990;245;1:47–49. doi: 10.1016/0165-7992(90)90024-e.
26. Romodin L.A., Lysenko N.P. The Radioprotective Effect of Chlorophyll-Based Drugs. Biophysics. 2022;67;1:78–84. doi: 10.1134/S0006350922010158.
27. Chiu L.C., Kong C.K., Ooi V.E. The Chlorophyllin-Induced Cell Cycle Arrest and Apoptosis in Human Breast Cancer MCF-7 Cells is Associated with ERK Deactivation and Cyclin D1 Depletion. International Journal of Molecular Medicine. 2005;16;4:735–740.
28. Chimploy K., Diaz G.D., Li Q., Carter O., Dashwood W.M., Mathews C.K., Williams D.E., Bailey G.S., Dashwood R.H. E2F4 and Ribonucleotide Reductase Mediate S-phase Arrest in Colon Cancer Cells Treated with Chlorophyllin. International Journal of Cancer. 2009;125;9:2086–2094. doi: 10.1002/ijc.24559.
29. Thiyagarajan P., Kavitha K., Thautam A., Dixit M., Nagini S. Dietary Chlorophyllin Abrogates TGFbeta Signaling to Modulate the Hallmark Capabilities of Cancer in an Animal Model of Forestomach Carcinogenesis. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35;7:6725–6737. doi: 10.1007/s13277-014-1849-5.
30. Das J., Samadder A., Mondal J., Abraham S.K., Khuda-Bukhsh A.R. Nano-Encapsulated Chlorophyllin Significantly Delays Progression OF Lung Cancer both in in Vitro and in Vivo Models through Activation of Mitochondrial Signaling Cascades and Drug-DNA Interaction. Environmental Toxicology and Pharmacology. 2016;46:147–157. doi: 10.1016/j.etap.2016.07.006.
31. Sun S., Zhang Y., Xu W., Yang R., Guo J., Guan S., Ma Q., Ma K., Xu J. Chlorophyllin Inhibits Mammalian Thioredoxin Reductase 1 and Triggers Cancer Cell Death. Antioxidants. 2021;10;11:1733. doi: 10.3390/antiox10111733.
32. Il’in L.A., Rudnyy N.M., Suvorov N.N., Chernov G.A., Antipov V.V., Vasin M.V., Davydov B.I., Mikhaylov P.P. Indralin – Radioprotektor Ekstrennogo Deystviya. Protivoluchevyye Svoystva, Farmakologiya, Mekhanizm Deystviya, Klinika = Indralin is a Emergency Radioprotector. Anti-Radiation Properties, Pharmacology, Mechanism of Action, Clinic. Moscow Publ., 1994. 436 p. (In Russ.).
33. Vasin M.V. B-190 (Indralin) in the Light of History of Formation of Ideas of the Mechanism of Action of Radioprotectors. Radiacionnaya Biologiya. Radioekologiya. 2020;60;4:378–395 (In Russ.). doi: 10.31857/S0869803120040128.
34. Romodin L.A., Nikitenko O.V., Bychkova T.M., Zrilova Yu.A., Rodionova E.D., Bocharov D.A. Radioprotective Properties of Riboxin (Inosine) and Indralin under External Irradiation. Bulletin of Experimental Biology and Medicine. 2023;176;11:585–588 (In Russ.). doi: 10.47056/0365-9615-2023-176-11-585-588
35. Legeza V.I., Grebenyuk A.N., Zargarova N.I. To a Question on Efficiency of Application of Radioprotectors with Various Mechanisms of Action in Injures Typical for Radiation Accidents (Experimental Research). Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2013;1:42–47 (In Russ.).
36. Grebenyuk A.N., Myasnikov V.A., Zatsepin V.V., Aksenova N.V., Bykov V.N., Sidorov D.A. Comparative Study of the Effectiveness of Heparin, Interleukin-1β, Β-Estradiol and Indometofen as Radioprotectors in Acute Irradiation. Bulletin of the Russian Military Medical Academy. 2011;4(36):101–104 (In Russ.).
37. Filimonova M.V., Shevchenko L.I., Makarchuk V.M., Chesnakova E.A., Izmest’eva O.S., Korneeva T.S., Filimonov A.S. Radioprotective Properties of NO-Synthase Inhibitor T1023: I. Indicators of Radioprotective Activity and Interaction with Other Radioprotectors. Radiacionnaya Biologiya. Radioekologiya. 2015;55;3:250–259 (In Russ.). doi: 10.7868/S0869803115030042.
38. Zhang Y., Huang Q., Xu Q., Jia C., Xia Y. Pimavanserin Tartrate Induces Apoptosis and Cytoprotective Autophagy and Synergizes with Chemotherapy on Triple Negative Breast Cancer. Biomedicine & Pharmacotherapy. 2023;168:115665. doi: 10.1016/j.biopha.2023.115665.
39. Lecureur V., Le Thiec A., Le Meur A., Amiot L., Drenou B., Bernard M., Lamy T., Fauchet R., Fardel O. Potassium Antimonyl Tartrate Induces Caspase- and Reactive Oxygen Species-Dependent Apoptosis in Lymphoid Tumoral Cells. British Journal of Haematology. 2002;119;3:608–615. doi: 10.1046/j.1365-2141.2002.03863.x.
40. Lecureur V., Lagadic-Gossmann D., Fardel O. Potassium Antimonyl Tartrate Induces Reactive Oxygen Species-Related Apoptosis in Human Myeloid Leukemic HL60 Cells. International Journal of Oncology. 2002;20;5:1071–1076.
41. Chang S.H., Lee A.Y., Yu K.N., Park J., Kim K.P., Cho M.H. Dihydroergotamine Tartrate Induces Lung Cancer Cell Death through Apoptosis and Mitophagy. Chemotherapy. 2016;61;6:304–312. doi: 10.1159/000445044.
42. Elmetwalli A., Hashish S.M., Hassan M.G., El-Magd M.A., El-Naggar S.A., Tolba A.M., Salama A.F. Modulation of the Oxidative Damage, Inflammation, and Apoptosis-Related Genes by Dicinnamoyl-L-tartaric Acid in Liver Cancer. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2023;396;11:3087–3099. doi: 10.1007/s00210-023-02511-8.
43. Fuchs H., Jahn K., Hu X., Meister R., Binter M., Framme C. Breaking a Dogma: High-Throughput Live-Cell Imaging in Real-Time with Hoechst 33342. Advanced Healthcare Materials. 2023;12;20:e2300230. doi: 10.1002/adhm.202300230.
44. Cordeiro M.M., Filipe H.A.L., Santos P.D., Samelo J., Ramalho J.P.P., Loura L.M.S., Moreno M.J. Interaction of Hoechst 33342 with POPC Membranes at Different pH Values. Molecules. 2023;28;15:5640. doi: 10.3390/molecules28155640.
45. Vasin M.V., Ushakov I.B. Potential Ways of Increase in Bogy Resistance to Damaging Actionof Ionizing Radiation with the Aids of Radiomitigators. Uspekhi Sovremennoy Biologii. 2019;139;3:235–253 (In Russ.). doi: 10.1134/S0042132419030098.
46. Srinivasan S., Torres A.G., Ribas de Pouplana L. Inosine in Biology and Disease. Genes. 2021;12;4:600. doi: 10.3390/genes12040600.
47. Zhuravlyov A.I., Zubkova S.M. Antioksidanty. Svobodnoradikal’naya Patologiya, Starenie = Antioxidants. Free Radical Pathology, Aging. Second edition, revised and expanded. Moscow, Belye Al’vy Publ., 2014. 304 p. (In Russ.).
48. Zhuravlyov A.I. Kvantovaya Biofizika Zhivotnykh I Cheloveka: Svechenie Zhivykh Tkaney = Quantum Biophysics of Animals and Humans: The Glow of Living Tissues. Moscow, BINOM. Laboratoriya Znaniy Publ., 2014. 400 p. (In Russ.).
49. Hutchison J.C., Evans J., Edgell T.A., Nie G., Gardner D.K., Salamonsen L.A. Detrimental Actions of Obesity-Associated Advanced Glycation End-Products on Endometrial Epithelial Cell Proliferation are Alleviated by Antioxidants. Reproductive Biomedicine Online. 2023;47;1:35–50. doi: 10.1016/j.rbmo.2023.01.021.
50. Raj M.H., Abd Elmageed Z.Y., Zhou J., Gaur R.L., Nguyen L., Azam G.A., Braley P., Rao P.N., Fathi I.M., Ouhtit A. Synergistic Action of Dietary Phyto-Antioxidants on Survival and Proliferation of Ovarian Cancer Cells. Gynecologic Oncology. 2008;110;3:432–438. doi: 10.1016/j.ygyno.2008.05.001.
51. Asay S., Graham A., Hollingsworth S., Barnes B., Oblad R.V., Michaelis D.J., Kenealey J.D. Gamma-Tocotrienol and Alpha-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells. Molecules. 2020;25;2:398. doi: 10.3390/molecules25020398.
52. Liu K.Y., Wang Q., Nakatsu C.H., Jones-Hall Y., Jiang Q. Combining Gamma-Tocopherol and Aspirin Synergistically Suppresses Colitis-Associated Colon Tumorigenesis and Modulates the Gut Microbiota in Mice, and Inhibits the Growth of Human Colon Cancer Cells. European Journal of Pharmacology. 2023;946:175656. doi: 10.1016/j.ejphar.2023.175656.
53. Ardelt B., Kunicki J., Traganos F., Darzynkiewicz Z. Chlorophyllin Protects Cells from the Cytostatic and Cytotoxic Effects of Quinacrine Mustard but Not of Nitrogen Mustard. International Journal of Oncology. 2001;18;4:849–853. doi: 10.3892/ijo.18.4.849.
54. Kouvaris J.R., Kouloulias V.E., Vlahos L.J. Amifostine: the First Selective-Target and Broad-Spectrum Radioprotector. The Oncologist. 2007;12;6:738–747. doi: 10.1634/theoncologist.12-6-738.
55. Buzgan N.G., Semenenko O.F., Dorosevich A.E. Influence of Acetylcholine and Adrenergic Receptors on Development and Progression of Non-Small Cell Lung Cancer. Voprosy Onkologii. 2016;62;5:694–700 (In Russ.).
56. Fatyukhina O.E., Kolokol’tsova T.D., Troshkova G.P. Safety Assessment of the Laser-Induced Fluorescence Method Based on a Human Diploid Cell Culture Model. Kletochnyye Tekhnologii v Biologii i Meditsine. 2007;4:203–206 (In Russ.).
57. Povolyaeva O.S., Chadaeva A.A., Lunitsin A.V., Yurkov S.G. Dwarf bat’s (Pipistrellus Pipistrellus) Lung Diploid Cell Strains and their Permissivity to Orbiviruses (Reoviridae: Orbivirus) – Pathogens of Vector-Borne Animal Diseases. Problems of Virusology. 2022;67;3:227–236 (In Russ.). doi: 10.36233/0507-4088-114.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The research was carried out at the expense of a grant from the Russian Science Foundation No. 23-24-00383, https://rscf.ru/project/23-24-00383 /.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-35-45
A.V. Rodina
The Mitochondrial 18 kDa Translocator Protein
as a Biomarker of Radiation-Induced Neuroinflammatory
NRC Kurchatov Institute, Moscow, Russia
Contact person: A.V. Rodina, е-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
CONTENTS
The review presents current knowledge about the structure of the18 kDa translocator protein TSPO, its polymorphic variants, regulation of its gene expression and function in the cells of CNS. Particular attention is paid to its role in mitochondrial homeostasis in microglia under neuroinflammation in the long-term period after ionizing radiation exposure. Data on the effectiveness of several TSPO ligands for diagnostic imaging and treatment of neuroinflammation for restoring cognitive functions in neurodegenerative pathologies are summarized. Based on the TSPO level in the brain and in the peripheral blood cells late after irradiation, TSPO is discussed as a potential marker of neuroinflammation development.
Keywords: ionizing radiation, radiation-induced neuroinflammation, microglia, translocator protein TSPO, positron emission tomography, radioligand
For citation: Rodina AV. The Mitochondrial 18 kDa Translocator Protein as a Biomarker of Radiation-Induced Neuroinflammatory. Medical Radiology and Radiation Safety. 2024;69(3):35–45. (In Russian). DOI:10.33266/1024-6177-2024-69-3-35-45
References
1. Betlazar C, Middleton RJ, Banati RB, Liu GJ. The Impact of High and Low Dose Ionising Radiation on the Central Nervous System. Redox Biol. 2016;9:144-56. doi: 10.1016/j.redox.2016.08.002.
2. Liu Q, Huang Y, Duan M, Yang Q, Ren B, Tang F. Microglia as Therapeutic Target for Radiation-Induced Brain Injury. International Journal of Molecular Sciences. 2022;23(15). doi: 10.3390/ijms23158286.
3. Maeda J, Higuchi M, Inaji M, Ji B, Haneda E, Okauchi T, et al. Phase-Dependent Roles of Reactive Microglia and Astrocytes in Nervous System Injury as Delineated by Imaging of Peripheral Benzodiazepine Receptor. Brain Research. 2007;1157:100-11. doi: 10.1016/j.brainres.2007.04.054.
4. Betlazar C, Middleton RJ, Banati R, Liu GJ. The Translocator Protein (TSPO) in Mitochondrial Bioenergetics and Immune Processes. Cells. 2020;9(2). doi: 10.3390/cells9020512.
5. Braestrup C, Squires RF. Specific Benzodiazepine Receptors in Rat Brain Characterized by High-Affinity (3h)Diazepam Binding. Proceedings of the National Academy of Sciences of the United States of America. 1977;74(9):3805-9. doi: 10.1073/pnas.74.9.3805.
6. Mukhin AG, Papadopoulos V, Costa E, Krueger KE. Mitochondrial Benzodiazepine Receptors Regulate Steroid Biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(24):9813-6. doi: 10.1073/pnas.86.24.9813.
7. Sprengel R, Werner P, Seeburg PH, Mukhin AG, Santi MR, Grayson DR, et al. Molecular Cloning and Expression of CDNA Encoding a Peripheral-Type Benzodiazepine Receptor. The Journal of Biological Chemistry. 1989;264(34):20415-21. doi:
8. Gatliff J, Campanella M. TSPO: Kaleidoscopic 18-Kda Amid Biochemical Pharmacology, Control and Targeting of Mitochondria. The Biochemical Journal. 2016;473(2):107-21. doi: 10.1042/bj20150899.
9. Li F, Liu J, Liu N, Kuhn LA, Garavito RM, Ferguson-Miller S. Translocator Protein 18 kDa (TSPO): an Old Protein with New Functions? Biochemistry. 2016;55(20):2821-31. doi: 10.1021/acs.biochem.6b00142.
10. Papadopoulos V, Fan J, Zirkin B. Translocator Protein (18 kDa): an Update on its Function in Steroidogenesis. Journal of Neuroendocrinology. 2018;30(2). doi: 10.1111/jne.12500.
11. Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu GJ. Cellular Sources and Regional Variations in the Expression of the Neuroinflammatory Marker Translocator Protein (TSPO) in the Normal Brain. International Journal of Molecular Sciences. 2018;19(9). doi: 10.3390/ijms19092707.
12. Notter T, Schalbetter SM, Clifton NE, Mattei D, Richetto J, Thomas K, et al. Neuronal Activity Increases Translocator Protein (TSPO) Levels. Molecular Psychiatry. 2021;26(6):2025-37. doi: 10.1038/s41380-020-0745-1.
13. Boyd A, Byrne S, Middleton RJ, Banati RB, Liu GJ. Control of Neuroinflammation through Radiation-Induced Microglial Changes. Cells. 2021;10(9). doi: 10.3390/cells10092381.
14. Milenkovic VM, Slim D, Bader S, Koch V, Heinl ES, Alvarez-Carbonell D, et al. CRISPR-Cas9 Mediated TSPO Gene Knockout alters Respiration and Cellular Metabolism in Human Primary Microglia Cells. International Journal of Molecular Sciences. 2019;20(13). doi: 10.3390/ijms20133359.
15. Loth MK, Guariglia SR, Re DB, Perez J, de Paiva VN, Dziedzic JL, et al. A Novel Interaction of Translocator Protein 18 kDa (TSPO) with NADPH Oxidase in Microglia. Mol Neurobiol. 2020;57(11):4467-87. doi: 10.1007/s12035-020-02042-w.
16. Lee Y, Park Y, Nam H, Lee JW, Yu SW. Translocator Protein (TSPO): the New Story of the Old Protein in Neuroinflammation. BMB Reports. 2020;53(1):20-7. doi: 10.5483/BMBRep.2020.53.1.273.
17. Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan R, Pham T, et al. The 18 kDa Translocator Protein, Microglia and Neuroinflammation. Brain Pathology (Zurich, Switzerland). 2014;24(6):631-53. doi: 10.1111/bpa.12196.
18. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1-5. doi: 10.1038/jcbfm.2011.147.
19. Werry EL, Bright FM, Piguet O, Ittner LM, Halliday GM, Hodges JR, et al. Recent Developments in TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences. 2019;20(13). doi: 10.3390/ijms20133161.
20. Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in Vivo Glial Activation in Patients with Amyotrophic Lateral Sclerosis: Assessed with [(11)C]-PBR28. NeuroImage Clinical. 2015;7:409-14. doi: 10.1016/j.nicl.2015.01.009.
21. Suridjan I, Pollock BG, Verhoeff NP, Voineskos AN, Chow T, Rusjan PM, et al. In-Vivo Imaging of Grey and White Matter Neuroinflammation in Alzheimer’s Disease: a Positron Emission Tomography Study with a Novel Radioligand, [18F]-FEPPA. Mol Psychiatry. 2015;20(12):1579-87. doi: 10.1038/mp.2015.1.
22. Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, et al. In Vivo Radioligand Binding to Translocator Protein Correlates with Severity of Alzheimer’s Disease. Brain: a Journal of Neurology. 2013;136(Pt 7):2228-38. doi: 10.1093/brain/awt145.
23. Datta G, Colasanti A, Kalk N, Owen D, Scott G, Rabiner EA, et al. (11)C-PBR28 and (18)F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2017;58(9):1477-82. doi: 10.2967/jnumed.116.187161.
24. Da Pozzo E, Costa B, Martini C. Translocator Protein (TSPO) and Neurosteroids: Implications in Psychiatric Disorders. Current Molecular Medicine. 2012;12(4):426-42. doi: 10.2174/156652412800163451.
25. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C, et al. Translocator Protein (18 kD) as Target for Anxiolytics without Benzodiazepine-Like Side Effects. Science (New York, NY). 2009;325(5939):490-3. doi: 10.1126/science.1175055.
26. Costa B, Pini S, Martini C, Abelli M, Gabelloni P, Landi S, et al. Ala147Thr Substitution in Translocator Protein is Associated with Adult Separation Anxiety in Patients with Depression. Psychiatric Genetics. 2009;19(2):110-1. doi: 10.1097/YPG.0b013e32832080f6.
27. Owen DR, Fan J, Campioli E, Venugopal S, Midzak A, Daly E, et al. TSPO Mutations in Rats and a Human Polymorphism Impair the Rate of Steroid Synthesis. The Biochemical Journal. 2017;474(23):3985-99. doi: 10.1042/bcj20170648.
28. Prossin AR, Chandler M, Ryan KA, Saunders EF, Kamali M, Papadopoulos V, et al. Functional TSPO Polymorphism Predicts Variance in the Diurnal Cortisol Rhythm in Bipolar Disorder. Psychoneuroendocrinology. 2018;89:194-202. doi: 10.1016/j.psyneuen.2018.01.013.
29. Guo Y, Kalathur RC, Liu Q, Kloss B, Bruni R, Ginter C, et al. Protein Structure. Structure and Activity of Tryptophan-Rich TSPO Proteins. Science (New York, NY). 2015;347(6221):551-5. doi: 10.1126/science.aaa1534.
30. Batarseh A, Papadopoulos V. Regulation of Translocator Protein 18 kDa (TSPO) Expression in Health and Disease States. Molecular and Cellular Endocrinology. 2010;327(1-2):1-12. doi: 10.1016/j.mce.2010.06.013.
31. Hanisch UK, Kettenmann H. Microglia: Active Sensor and Versatile Effector Cells in The Normal and Pathologic Brain. Nature Neuroscience. 2007;10(11):1387-94. doi: 10.1038/nn1997.
32. Gao C, Jiang J, Tan Y, Chen S. Microglia in Neurodegenerative Diseases: Mechanism and Potential Therapeutic Targets. Signal Transduction and Targeted Therapy. 2023;8(1):359. doi: 10.1038/s41392-023-01588-0.
33. Monga S, Nagler R, Amara R, Weizman A, Gavish M. Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation. Cells. 2019;8(5). doi: 10.3390/cells8050486.
34. Turnquist C, Harris BT, Harris CC. Radiation-Induced Brain Injury: Current Concepts and Therapeutic Strategies Targeting Neuroinflammation. Neuro-oncology Advances. 2020;2(1):vdaa057. doi: 10.1093/noajnl/vdaa057.
35. Hladik D, Tapio S. Effects of Ionizing Radiation on the Mammalian Brain. Mutation Research Reviews in Mutation Research. 2016;770(Pt B):219-30. doi: 10.1016/j.mrrev.2016.08.003.
36. Betlazar C, Middleton RJ, Howell N, Storer B, Davis E, Davies J, et al. Mitochondrial Translocator Protein (TSPO) Expression in the Brain after Whole Body Gamma Irradiation. Frontiers in Cell and Developmental Biology. 2021;9:715444. doi: 10.3389/fcell.2021.715444.
37. Родина АВ, Семочкина ЮП, Копаева МЮ, Стрепетов АН, Сафронов ВВ, Москалева ЕЮ. Состояние микроглии и когнитивные функции у мышей в отдаленный период после сочетанного действия низких доз гамма- и гамма-нейтронного излучения // Авиакосмическая и экологическая медицина. 2019. Т.53, №4. С. 65-73. [Rodina AV, Semochkina UP, Kopaeva MY, Strepetov AN, Safronov VV, Moskaleva EY. The State of Microglia and Cognitive Functions in Mice in the Long-Term Period after Combined Exposure to Low Doses of Gamma and Gamma Neutron Radiation. Aviakosmicheskaya i Ekologicheskaya Meditsina. 2019;53(4):65-73 (In Russ.)].
38. Rodina AV, Semochkina YP, Vysotskaya OV, Parfenova AA, Moskaleva EY. Radiation-induced Neuroinflammation Monitoring by the Level of Peripheral Blood Monocytes with High Expression of Translocator Protein. Int J Radiat Biol. 2023;99(9):1364-77. doi: 10.1080/09553002.2023.2177765.
39. Zhirnik AS SO, Semochkina JP, Shibaeva KD, Rodina AV, Ratushnjak MG, Moskaleva EJ. Cognitive Impairment and Induction of Neuroinflammation in the Late Period after Single Whole Brain γ-Irradiation of Mice. Radiatsionnaya Biologiya Radioekologiya. 2021;61(1):32-43.
40.Nutma E, Stephenson JA, Gorter RP, de Bruin J, Boucherie DM, Donat CK, et al. A Quantitative Neuropathological Assessment of Translocator Protein Expression in Multiple Sclerosis. Brain: a Journal of Neurology. 2019;142(11):3440-55. doi: 10.1093/brain/awz287.
41. Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A. Characterization of the 18 kDa Translocator Protein (TSPO) Expression in Post-Mortem Normal and Alzheimer’s Disease Brains. Brain pathology (Zurich, Switzerland). 2020;30(1):151-64. doi: 10.1111/bpa.12763.
42. Kreisl WC, Kim MJ, Coughlin JM, Henter ID, Owen DR, Innis RB. PET Imaging of Neuroinflammation in Neurological Disorders. Lancet Neurol. 2020;19(11):940-50. doi: 10.1016/S1474-4422(20)30346-X.
43. Nettis MA, Veronese M, Nikkheslat N, Mariani N, Lombardo G, Sforzini L, et al. PET Imaging Shows No Changes in TSPO Brain Density after IFN-α Immune Challenge in Healthy Human Volunteers. Transl Psychiatry. 2020;10(1):89. doi: 10.1038/s41398-020-0768-z.
44. Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and its Clinical Impact in Neurodegenerative Diseases. International Journal of Molecular Sciences. 2017;18(4). doi: 10.3390/ijms18040785.
45. Soustiel JF, Zaaroor M, Vlodavsky E, Veenman L, Weizman A, Gavish M. Neuroprotective Effect of Ro5-4864 Following Brain Injury. Experimental Neurology. 2008;214(2):201-8. doi: 10.1016/j.expneurol.2008.08.008.
46. Shiotani T, Nakamoto Y, Watabe S, Yoshii M, Nabeshima T. Anticonvulsant Actions of Nefiracetam on Epileptic EL Mice and Their Relation to Peripheral-Type Benzodiazepine Receptors. Brain Research. 2000;859(2):255-61. doi: 10.1016/s0006-8993(00)01971-5.
47. Parente A, de Vries EFJ, van Waarde A, Ioannou M, van Luijk P, Langendijk JA, et al. The Acute and Early Effects of Whole-Brain Irradiation on Glial Activation, Brain Metabolism, and Behavior: a Positron Emission Tomography Study. Molecular Imaging and Biology. 2020;22(4):1012-20. doi: 10.1007/s11307-020-01483-y.
48. Ma L, Zhang H, Liu N, Wang PQ, Guo WZ, Fu Q, et al. TSPO Ligand PK11195 Alleviates Neuroinflammation and Beta-Amyloid Generation Induced by Systemic LPS Administration. Brain Research Bulletin. 2016;121:192-200. doi: 10.1016/j.brainresbull.2016.02.001.
49. Scarf AM, Ittner LM, Kassiou M. The Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design. Journal of Medicinal Chemistry. 2009;52(3):581-92. doi: 10.1021/jm8011678.
50. Ferzaz B, Brault E, Bourliaud G, Robert JP, Poughon G, Claustre Y, et al. SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a Peripheral Benzodiazepine Receptor Ligand, Promotes Neuronal Survival and Repair. The Journal of Pharmacology and Experimental Therapeutics. 2002;301(3):1067-78. doi: 10.1124/jpet.301.3.1067.
51. Thominiaux C, Damont A, Kuhnast B, Demphel S, Le Helleix S, Boisnard S, et al. Radiosynthesis of 7-chloro-N,N-dimethyl-5-[11C]methyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, [11C]SSR180575, a Novel Radioligand for Imaging the TSPO (peripheral benzodiazepine receptor) with PET. Journal of Labelled Compounds and Radiopharmaceuticals. 2010;53(13):767-73. doi: https://doi.org/10.1002/jlcr.1794.
52. Chauveau F, Boutin H, Van Camp N, Thominiaux C, Hantraye P, Rivron L, et al. In Vivo Imaging of Neuroinflammation in the Rodent Brain with [11C]SSR180575, a Novel Indoleacetamide Radioligand of the Translocator Protein (18 kDa). Eur J Nucl Med Mol Imaging. 2011;38(3):509-14. doi: 10.1007/s00259-010-1628-5.
53. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, et al. Increased Binding of Peripheral Benzodiazepine Receptor in Alzheimer’s Disease Measured by Positron Emission Tomography with [11C]DAA1106. Biological Psychiatry. 2008;64(10):835-41. doi: 10.1016/j.biopsych.2008.04.021.
54. Kim K, Kim H, Bae S-H, Lee S-Y, Kim Y-H, Na J, et al. CB251 PET/MR Imaging Probe Targeting Translocator Protein (TSPO) Independent of its Polymorphism in a Neuroinflammation Model. Theranostics. 2020;10(20):9315-31. doi: 10.7150/thno.46875.
55. Sutton JA, Clauss RP. A Review of the Evidence of Zolpidem Efficacy in Neurological Disability after Brain Damage Due to Stroke, Trauma and Hypoxia: a Justification of Further Clinical Trials. Brain Injury. 2017;31(8):1019-27. doi: 10.1080/02699052.2017.1300836.
56. Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, et al. Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2016;57(11):1753-9. doi: 10.2967/jnumed.115.169078.
57. Scholz R, Caramoy A, Bhuckory MB, Rashid K, Chen M, Xu H, et al. Targeting Translocator Protein (18 kDa) (TSPO) Dampens Pro-Inflammatory Microglia Reactivity in the Retina and Protects from Degeneration. Journal of Neuroinflammation. 2015;12(1):201. doi: 10.1186/s12974-015-0422-5.
58. Li XB, Guo HL, Shi TY, Yang L, Wang M, Zhang K, et al. Neuroprotective Effects of a Novel Translocator Protein (18 kDa) Ligand, ZBD-2, against Focal Cerebral Ischemia and NMDA-Induced Neurotoxicity. Clinical and Experimental Pharmacology & Physiology. 2015;42(10):1068-74. doi: 10.1111/1440-1681.12460.
59. Stein DJ. Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial. Advances in Therapy. 2015;32(1):57-68. doi: 10.1007/s12325-015-0176-6.
60. Barron AM, Garcia-Segura LM, Caruso D, Jayaraman A, Lee JW, Melcangi RC, et al. Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer’s Disease. J Neurosci. 2013;33(20):8891-7. doi: 10.1523/jneurosci.1350-13.2013.
61. Delage C, Vignal N, Guerin C, Taib T, Barboteau C, Mamma C, et al. From Positron Emission Tomography to Cell Analysis of the 18-kDa Translocator Protein in Mild Traumatic Brain Injury. Sci Rep. 2021;11(1):24009. doi: 10.1038/s41598-021-03416-3.
62. Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, et al. In Vivo Evidence of a Functional Association Between Immune Cells in Blood and Brain in Healthy Human Subjects. Brain Behav Immun. 2016;54:149-57. doi: 10.1016/j.bbi.2016.01.019.
63. Canat X, Carayon P, Bouaboula M, Cahard D, Shire D, Roque C, et al. Distribution Profile and Properties of Peripheral-Type Benzodiazepine Receptors on Human Hemopoietic Cells. Life Sci. 1993;52(1):107-18. doi: 10.1016/0024-3205(93)90293-c.
64. Sultana N, Sun C, Katsube T, Wang B. Biomarkers of Brain Damage Induced by Radiotherapy. Dose-response: a Publication of International Hormesis Society. 2020;18(3):1559325820938279. doi: 10.1177/1559325820938279.
65. Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of Radiotherapy-Associated Cognitive Disability in Patients with Brain Tumours. Nat Rev Neurol. 2017;13(1):52-64. doi: 10.1038/nrneurol.2016.185.
66. Engler H, Brendt P, Wischermann J, Wegner A, Rohling R, Schoemberg T, et al. Selective Increase of Cerebrospinal Fluid IL-6 during Experimental Systemic Inflammation in Humans: Association with Depressive Symptoms. Mol Psychiatry. 2017;22(10):1448-54. doi: 10.1038/mp.2016.264.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The work was carried out within the state assigment of NRC «Kurchatov institute».
Contribution. The article was prepared with the sole participation of the author.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-53-56
A.R. Tukov, I.L. Shafranskii, A.N. Koterov,
M.N. Ziyatdinov, O.N. Prokhorova, A.M. Mikhaylenko
Evaluation of the Radiation Risk of Death from Cardiovascular Diseases among the Liquidators Involved in the Cleaning up of the Consequences of the Chernobyl Accident – Workers in the Nuclear Industry Sector
A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Alexander Romanovich Tukov, email This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Background: Assessment of the risk of death from circulatory system diseases due to radiation exposure in liquidators of the Chernobyl accident consequences (hereinafter referred to as liquidators) using data on doses of various types of exposure.
Material and methods: The work used the information base of the Industry Register of persons exposed to radiation as a result of the accident at the Chernobyl nuclear power plant (hereinafter referred to as the register), nuclear industry workers. The radiation risk assessment study included men - 12,706 liquidators who had data on external emergency radiation doses when working in the 30 km Chernobyl NPP zone, 1,327 of them had data on occupational radiation doses. Poisson regression was chosen as the statistical model of risk.
The study covers the period from 1987 to 2021. During the observation period, the register accumulated 304,023 person/years. The majority of the register in 1986 was made up of men – 84.7 %, women – 15.3 %.
Results: When data on doses of different types of radiation are used to calculate doses, different results of excess relative risk are obtained. Only the total radiation dose (occupational, emergency, medical, natural) can provide correct results for calculating the radiation risk of death from radiation-induced diseases.
Conclusion: The prospect of research should be considered to be filling the information base of the Industry Register with data on doses of all types of radiation.
Keywords: Chernobyl accident, liquidators, circulatory diseases, mortality, radiation risk, nuclear industry
For citation: Tukov AR, Shafransky IL, Koterov AN, Ziyatdinov MN, Prokhorova ON, Mikhaylenko AM. Evaluation of the Radiation Risk of Death from Cardiovascular Diseases among the Liquidators Involved in the Cleaning up of the Consequences of the Chernobyl Accident – Workers in the Nuclear Industry Sector. Medical Radiology and Radiation Safety. 2024;69(3):53–56. (In Russian). DOI:10.33266/1024-6177-2024-69-3-53-56
References
1. UNSCEAR 2019. Report to the General Assembly, with Scientific Annexes. Annex A. Evaluation of Selected Health Effects and Inference of Risk Due to Radiation Exposure. New York. 2020;21–192.
2. Baselet B, Ramadan R, Benotmane A. Selected Endothelial Responses after Ionizing Radiation Exposure. Endothelial Dysfunction – Old Concepts and New Challenges. Ed.: Lenasi H. IntechOpen, 2018. P. 365–390. DOI: 10.5772/intechopen.72386.
3. Здравоохранение в России. 2021: Стат.сб. Росстат. М., 2021. 171 с. [Health Care in Russia. Statistical Collection. Moscow Publ., 2021. 171 p. (In Russ.)]
4. Kochanek K, Murphy S L, Xu J, Tejada-Vera B. Deaths: Final Data for 2014. National Vital Statistics Reports. 2016; 65(2). 122 p.
5. Arias E, Xu J, Tejada-Vera B, Bastian B. U.S. State Life Tables, 2019. National Vital Statistics Reports. 2019;(18):18.
6. ICRP Publication 118. ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold Doses for Tissue Reactions in a Radiation Protection Context. Annals of the ICRP. Ed Clement C.H. Amsterdam – New York; Elsevier, 2012. 325 p.
7. Little M, Azizova T, Richardson D, et al. Ionising Radiation and Cardiovascular Disease: Systematic Review and Meta-Analysis. Brit. Med. J. 2023;380:81. DOI:10.1136/bmj-2022-072924.
8. Bernstein J, Dauer L, Dauer Z. Cardiovascular Risk from Low Dose Radiation Exposure. Review and Scientific Appraisal of the Literature. 3002018408. Technical Report. Palo Alto (CA): Electric Power Research Institute (EPRI). Final Report, 2020. 144 p.
9. McGale P, Darby S. Low Doses of Ionizing Radiation and Circulatory Diseases: a Systematic Review of the Published Epidemiological Evidence. Radiat. Res. 2005;163(3):247–257. DOI: 10.1667/rr3314.
10. UNSCEAR 2006. Report to the General Assembly, with Scientific Annexes. Annex B Epidemiological Evaluation of Cardiovascular Disease and Other Non-Cancer Diseases Following Radiation Exposure. United Nations. New York, 2008. P. 325–383.
11. UNSCEAR 2010. Report of the United Nations Scientific Committee on the Effects of Atomic Radiation 2010. Fifty-Seventh Session, Includes Scientific Report: Summary of Low-Dose Radiation Effects on Health. United Nations. New York, 2011. 106 p.
12. Wakeford R. Does Low-Level Exposure to Ionizing Radiation Increase the Risk of Cardiovascular Disease? Hypertension. 2019;73(6):1170–1171. DOI: 10.1161/HYPERTENSIONAHA.119.11892.
13. NCRP Commentary No 27. Implications of Recent Epidemiologic Studies for the Linear-Nonthreshold Model and Radiation Protection. National Council on Radiation Protection and Measurements: Bethesda, MD, 2018. 87 p.
14. Azizova T, Haylock R, Moseeva M., et al. Cerebrovascular Diseases Incidence and Mortality in an Extended Mayak Worker Cohort 1948–1982. Radiat. Res. 2014;182(5):529–544. DOI:10.1667/RR13680.1.
15. Preston D.L., Lubin J.H., Pierce D.A., McConney M.E. Epicure: User’s Guide. HiroSoft International Corporation. Seattle, WA 98112, USA, 1993. 329 p.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-46-52
A.M. Korelo, M.A. Maksioutov, S.Yu. Chekin, E.V. Kochergina, O.E. Lashkova
Analysis of the Influence of Radiation Exposure on Multimorbidity Among Liquidators of the Consequences of the Accident at the Chernobyl Nuclear Power Plant
A.F. Tsyb Medical Radiological Research Centre, Obninsk, Russia
Contact person: A.M. Korelo, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To give a general idea of the most common combinations of diseases in the male population of the Russian Federation and to identify the combinations of diseases, the development of which could be influenced by ionising radiation.
Material and methods: Cohort study of the influence of external gamma irradiation on multimorbidity of the Chernobyl accident liquidation participants according to the data of the National Radiation Epidemiological Registry. Multimorbidity was defined as the presence in one
participant of the cohort of two or more diseases from the list consisting of ten groups of diagnoses: diseases of lower respiratory tract, diseases of musculoskeletal system, diseases of endocrine system, mental disorders, oncology, neurology, diseases of digestive organs, diseases of cardiovascular system, diseases of genitourinary system, diseases of sense organs. The cohort consisted of men born between 1919 and 1969 who worked in the accident zone from 1986 to 1987 and had a documented whole-body external gamma dose. Cohort follow-up period: 1992–2021. The cohort size at the beginning of the follow-up was 59 290 people. The study participants were divided
into two groups according to external gamma dose: up to 150 mGy – 34602 individuals, 150 mGy and more – 24 688 individuals. For all possible combinations of diagnoses, relative radiation risk was calculated as a measure of the association of exposure with diseases. The relative radiation risk was considered statistically significant if the left border of the one-sided 95 % confidence interval was greater than 1. Statistical analyses were performed using the R programming language for statistical computing and the R arules package.
Results: During 30 years of follow-up, multimorbidity was noted in 62 % of individuals. The most common combinations of chronic diseases were combinations of cardiovascular diseases with digestive diseases (23 % of the original cohort), with lower respiratory diseases (22 %) and with musculoskeletal diseases (18 %). A combination of all four diagnosis groups was identified in 5 % of individuals. Nineteen multimorbid combinations with statistically significant relative radiation risk in the range (1.07–1.23) were identified.
Conclusions: No effect of radiation exposure on the number of individuals with multimorbidity was found, but in the studied cohort there are individuals with cardiovascular diseases, endocrine diseases, oncology and combinations of these groups of diagnoses with diseases of other body systems may be caused by radiation exposure. The statistically significant relative radiation risk for combinations of diagnoses is, in general, greater than for the individual diseases that make up these combinations.
Keywords: National Radiation Epidemiological Registry, multimorbidity, dose, external gamma radiation, Chernobyl accident liquidators, cohort study, relative radiation risk, baseline risk
For citation: Korelo AM, Maksioutov MA, Chekin SYu, Kochergina EV, Lashkova OE. Analysis of the Influence of Radiation Exposure on Multimorbidity Among Liquidators of the Consequences of the Accident at the Chernobyl Nuclear Power Plant. Medical Radiology and Radiation Safety. 2024;69(3):46–52. (In Russian). DOI:10.33266/1024-6177-2024-69-3-46-52
References
1. Voronin S.V., Cherkashin D.V., Bersheva I.V. Polymorbidity: Definition, Classification, Prevalence, Assessment Methods and Practical Significance. Vestnik Rossiyskoy Voyenno-Meditsinskoy Akademii = Bulletin of the Russian Military Medical Academy. 2018;4(64):243–248 (In Russ.).
2. Salive M.E. Multimorbidity in Older Adults. Epidemiol. Rev. 2013;35;1:75–83. DOI: 10.1093/epirev/mxs009.
3. Skou S.T., Mair F.S., Fortin M., Guthrie B., Nunes B.P., Miranda J.J., Boyd C.M., Pati S., Mtenga S., Smith S.M. Multimorbidity. Nat. Rev. Dis. Primers. 2022;8;1:1–22. DOI: 10.1038/s41572-022-00376-4.
4. Willadsen T.G., Siersma V., Nicolaisdóttir D.R., Køster-Rasmussen R., Jarbøl D.E., Reventlow S., Mercer S.W., Olivarius N.F. Multimorbidity and Mortality: A 15-year Longitudinal Registry-based Nationwide Danish Population Study. J. Comorb. 2018;8;1:2235042X18804063. DOI: 10.1177/2235042X18804063.
5. International Classification of Diseases 10th Revision (ICD-10). URL: https://mkb-10.com/ (Accessed 02.04.2024) (In Russ.).
6. Medical radiological consequences of Chernobyl: prognosis and evidence after 30 years. Ed. Ivanov V.K., Kaprin A.D. Moscow, GEOS Publ., 2015. 450 p. (In Russ.)
7. R Core Team (2023). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Austria, Vienna. URL: https://www.R-project.org/ (Accessed 02.04.2024).
8. Put Data into Production with Posit Connect. URL: https://posit.co/ (Accessed 02.04.2024).
9. Hahsler M., Grun B., Hornik K. Arules – A Computational Environment for Mining Association Rules and Frequent Item Sets. J. Stat. Softw. 2005;14;15:1–25. DOI: 10.18637/jss.v014.i15.
10. Zaki M.J., Parthasarathy S., Ogihara M., Li W. New Algorithms for Fast Discovery of Association Rules. Technical Report 651. Computer Science Department, University of Rochester. New York, 1997.
11. Agrawal R., Srikant R. Fast algorithms for mining association rules. Proceedings of the 20th International Conference on Very Large Data Bases, VLDB. Chile, Santiago, 1994. P. 487–499.
12. Georgiev G.Z. One-tailed vs Two-tailed Tests of Significance in A/B Testing. URL: https://blog.analytics-toolkit.com/2017/one-tailed-two-tailed-tests-significance-ab-testing/ (Accessed 02.04.2024).
13. Georgiev G.Z. Relative Risk Calculator. URL: https://www.gigacalculator.com/calculators/relative-risk-calculator.php (Accessed 02.04.2024).
14. Fortin M., Stewart M., Poitras M.E., Almirall J., Maddocks H. A Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. Ann. Fam. Med. 2012;10;2:142–151. DOI: 10.1370/afm.1337.
15. Hariri P., Clarke R., Bragg F., Chen Y., Guo Y., Yang L., Lv J., Yu C., Li L., Chen Z., Bennett D.A.; China Kadoorie Biobank Collaborative Group. Frequency and Types of Clusters of Major Chronic Diseases in 0.5 Million Adults in Urban and Rural China. J. Multimorb. Comorb. 2022;12:26335565221098327. DOI: 10.1177/26335565221098327.
16. Rothman K.J. Epidemiology: an Introduction. New York, Oxford University Press, 2002.
17. Andersen P.K., Geskus R.B., de Witte T., Putter H. Competing Risks in Epidemiology: Possibilities and Pitfalls. Int. J. Epidemiol. 2012;41;3:861–870. DOI:10.1093/ije/dyr213.
18. Kashcheev V.V., Chekin S.Yu., Karpenko S.V., Maksioutov M.A., Tumanov K.A., Kochergina E.V., Glebova S.E., Ivanov S.A., Kaprin A.D. Estimating of Radiation Risks of Malignant Neoplasms among Russian Chernobyl Cleanup Workers. Radiatsiya i Risk = Radiation and Risk. 2021;30;1:58–77 (In Russ.).
19. Chekin S.Yu., Maksioutov M.A., Kashcheev V.V., Karpenko S.V., Tumanov K.A., Kochergina E.V., Zelenskaya N.S., Lashkova O.E. Estimating of Radiation Risks Of Non-Cancer Diseases among Russian Chernobyl Cleanup Workers. Radiatsiya i Risk = Radiation and Risk. 2021;30;1:78–93 (In Russ.).
20. Gorskiy A.I., Chekin S.Yu., Maksyutov M.A., Karpenko S.V., Tumanov K.A., Zelenskaya N.S., Lashkova O.E. Statistical Relationship Between Radiation Dose and Radiation Risks Estimates for Non-Cancer Endocrine Diseases in Liquidators of the Chernobyl Accident with Account of Possible Wrong Diagnoses Established and Registered. Radiatsiya i Risk = Radiation and Risk. 2023;32;1:21–35 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-57-67
A.N. Koterov1, L.N. Ushenkova1, A.A. Wainson2, I.G. Dibirgadzhiev1,
M.V. Kalinina1, A.Yu. Bushmanov1
The Mortality Risk from Main Pathologies Due to Passive Smoking is not Achieved by the Overwhelming Majority of Nuclear Workers in All Periods of Employment
1 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
2 N.N. Blokhin Russian Cancer Research Center, Moscow
Contact person: Alexey N. Koterov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
To date, there are about 100 meta-analyses for lung cancer and circulatory (cardiovascular) diseases (CVD) as the effects of second hand smoking (SHS). The obtained risk values (Relative Risk – RR, odds ratio – OR, etc.) are in the range of 1.2–1.3, but there are no definitively accepted estimates yet, and many estimates were not made in recent years. Both SHS and work at nuclear industry enterprises have become stereotypes in everyday and scientific everyday consciousness, meaning something harmful in everyday and professional terms. The present study compared the mortality risks from all cancers, lung cancer, and CVD for SHS and nuclear workers (NW).
At the first stage, an umbrella review (review of reviews; overview) and meta-analyses of meta-analyses (meta-meta-analyses) on the risks of mortality from these pathologies as effects of SHS were performed. Umbrella review and meta-meta-analysis are regarded as the highest level of evidence and, thus, the identified risks can be conditionally considered as ‘standard’. There were insufficient data available for all cancer mortality rates after SHS; Therefore, the results from the meta-analysis by Kim A.S. et al, 2018 were used., and meta-meta-analyses were performed for lung cancer and CVD mortality. The risk values were in the range of 1.22–1.24, which replicates previous findings.
At the second stage, the risks identified for SHS were compared with the risks of mortality from the named pathologies for NW. The sample of publications for NW, extracted from the database maintained by the authors, included the most representative cohorts in relation to nuclear installations: with maximum doses, as well as combined cohorts (14–15 countries and INWORK – 3 countries). Based on published ERRs per 1 Gy for a given NW population, the radiation doses that NW would have to accumulate to approach the mortality risks from SHS were calculated.
To achieve SHS risks for all three disease types, NWs were found to need to receive radiation doses ranging from 129–183 mSv to 1.07–6.0 Sv. There have been no cases in which the risk from SHS was equivalent to exposure to low-dose radiation (up to 100 mGy); more often, doses were localized in the range of about 300–800 mSv, up to 6 Sv. Analysis of published data on dose distributions for NW has demonstrated that such doses are received either by a relatively small or vanishingly small proportion of NW. Risks for 80–96 % of NWs from various countries, including activities since the 1940s, did not reach the harms of chronic exposure to SHS.
It is concluded that the decades-long study of risks for NW, in particular ‘low doses’, does not seem adequate without taking into account the magnitude of even weak, but poorly controlled risks of everyday life, and the data obtained once again improves the image of employment in the field of nuclear energy.
Keywords: nuclear workers, mortality from diseases of the circulatory system, radiation, low doses, moderate doses, effect threshold
For citation: Koterov AN, Ushenkova LN, Wainson AA, Dibirgadzhiev IG, Kalinina MV, Bushmanov AYu. The Mortality Risk from Main Pathologies Due to Passive Smoking is not Achieved by the Overwhelming Majority of Nuclear Workers in All Periods of Employment. Medical Radiology and Radiation Safety. 2024;69(3):57–67. (In Russian). DOI:10.33266/1024-6177-2024-69-3-57-67
References
1. Smith G.D., Egger M. The First Reports on Smoking and Lung Cancer: Why are they Consistently Ignored? Bull. World Health Organ. 2005;83;10:799–800.
2. Bachinger E.,McKee M. Tobacco Policies in Austria during the Third Reich. Int. J. Tuberc. Lung Dis. 2007;11;9:1033–1037.
3. Brawley OW, Glynn TJ, Khuri FR, et al. The First Surgeon General’s Report on Smoking and Health: the 50th Anniversary. CA Cancer J. Clin. 2014;64;1:5–8. https://doi.org/10.3322/caac.21210.
4. Koterov A.N. Causal Criteria in Medical and Biological Disciplines: History, Essence and Radiation Aspect. Report 2. Henle-Koch Postulates and Criteria for Causality of Non-Communicable Pathologies before Hill. Radiats. Biol. Radioecol. = Radiation Biology. Radioecology. 2019;59;4:341–75 (In Russ.). https://doi.org/10.1134/S0869803119040052.
5. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Smoking. A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, DHHS Publication No. (CDC) 87-8398. USDHEW, 1986. 359 p. https://stacks.cdc.gov/view/cdc/20799 (accessed date: 2024/02/02).
6. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Washington, DC, 2006. 710 p. https://www.ncbi.nlm.nih.gov/books/NBK44324/pdf/Bookshelf_NBK44324.pdf (accessed date: 2024/02/02).
7. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death: Based on the Recommendations of the Ninth Revision Conference, 1975, and Adopted by the Twenty-ninth World Health Assembly, 1975 revision. Volume I. World Health Organization: Geneva, 1980. 758 p.
8. Classification of Diseases, Functioning, and Disability. CDC. Center for Disease Control and Prevention. NCHS. National Center for Health Statistics. World Health Organization (WHO). 2021. https://www.cdc.gov/nchs/icd/index.htm (accessed date: 2024/01/25).
9. Jadad A.R., Enkin M.W. Randomized Controlled Trials. Questions, Answers, and Musings. 2nd edition. Malden, Oxford, Carlton: BMJ Books, 2007. 136 p.
10. Blettner M., Sauerbrei W., Schlehofer B., Scheuchenpflug T., Friedenreich C. Traditional Reviews, Meta-Analyses and Pooled Analyses in Epidemiology. Int. J. Epidemiol. 1999;28;1:1–9. https://doi.org/10.1093/ije/28.1.1.
11. Boderie N.W., Sheikh A., Lo E., Sheikh A., Burdorf A., Van Lenthe F.J., et al. Public Support for Smoke-Free Policies in Outdoor Areas and (Semi-)Private Places: a Systematic Review and Meta-Analysis. EClinicalMedicine. 2023;59;Article101982:15p. https://doi.org/10.1016/j.eclinm.2023.101982.
12. Germain D. Exposure to and Perceptions of the Dangers and Illnesses of Passive Smoking among Victorians: 2004.CBRC Research Paper Series No.17. Site ‘Cancer Council Victoria’. https://www.cancervic.org.au/research/behavioural/research-papers/abstract_exposure_passive_smok.html (accessed date: 2024/02/02).
13. Koterov A.N., Ushenkova L.N., Zubenkova E.S., Waynson A.A., Kalinina M.V., Biryukov A.P. Strength of Association. Report 1. Graduation of Relative Risk. Medits. Radiologiya Radiat. Bezopasnost = Medical Radiology and Radiation Safety. 2019;64(4):5–17 (In Russ.). https://doi.org/10.12737/article_5d1adb25725023.14868717.
14. Koterov A.N. Causal Criteria In Medical And Biological Disciplines: History, Essence And Radiation Aspect. Report 3, Part 1: First Five Hill’s Criteria: Use and Limitations. Radiats. Biol. Radioecol. = Radiation Biology. Radioecology. 2021;61(3):300–32 (In Russ.) https://doi:10.31857/S0869803121030085.
15. Boffetta P., Jarvholm B., Brennan P., Nyren O. Incidence of Lung Cancer in a Large Cohort of Non-Smoking Men from Sweden. Int. J. Cancer. 2001;94;4:591–593. https://doi.org/10.1002/ijc.1507.
16. Wakelee H.A., Chang E.T., Gomez S.L., Keegan T.H., Feskanich D., Clarke C.A., et al. Lung Cancer Incidence in Never Smokers. J. Clin. Oncol. 2007;25;5:472–478. https://doi.org/10.1200/JCO.2006.07.2983.
17. SDR, Diseases of Circulatory System, All Ages, per 100,000. World Health Organization. European Health Information Gateway. URL: https://gateway.euro.who.int/en/indicators/hfa_101-1320-sdr-diseases-of-circulatory-system-all-ages-per-100-000/#id=19024 (accessed date: 2024/02/02).
18. Umbrella Reviews: Evidence Synthesis with Overviews of Reviews and Meta-Epidemiologic Studies. Ed. by G. Biondi-Zoccai. 1st Edition. Springer International Publishing, Switzerland, 2016. 526 p.
19. Trinquart L, Dechartres A, Ravaud P. Commentary: Meta-Epidemiology, Meta-Meta-Epidemiology or Network Meta-Epidemiology? Int. J. Epidemiol. 2013;42;4:1131–1133. https://doi.org/10.1093/ije/dyt137.
20. Sturmberg J.P. Evidence-Based Medicine – Not a Panacea for the Problems of a Complex Adaptive World. J. Eval. Clin. Pract. 2019;25;5:706–716. https://doi.org/10.1111/jep.13122.
21. Koterov A.N., Ushenkova L.N., Waynson A.A. Nuclear Workers — on the Question of Unification of Russian-Language Terminology (Brief Report). Medits. Radiologiya i Radiat. Bezopasnost = Medical Radiology and Radiation Safety. 2023;68;3:80–84 (In Russ.) https://doi.org/10.33266/1024-6177-2023-68-3-80-84.
22. ICRP Publication 118. ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold Doses for Tissue Reactions in a Radiation Protection Context. Annals of the ICRP. Ed. by C.H. Clement. Amsterdam – New York: Elsevier, 2012. 325 p.
23. Koterov A.N., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Brief Review of World Researches of Radiation and Non-Radiation Effects in Nuclear Industry Workers. Mediko-biologicheskiye Problemy Zhiznedeyatel’nosti = Medical and Biological Problems of Life Activity (Gomel). 2020;1:17–31 (In Russ.). https://doi.org/10.33266/2070-1004-2021-3-34-41.
24. Koterov A.N., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Comparison of the Risk of Mortality from Solid Cancers after Radiation Incidents and Occupational Exposures. Meditsina Katastrof = Disaster Medicine. 2021;3:34–41 (In Russ.). https://doi.org/10.33266/2070-1004-2021-3-34-41.
25. Koterov A.N., Tukov A.R., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Average Accumulated Radiation Doses for World Nuclear Workers: Low Doses, Low Effects. Comparison with Doses for Medical Radiologists. Radiatsionnaya Biologiya. Radioekologiya = Radiation biology. Radioecology. 2022;62;3:227–239. (In Russ.). https://doi.org/10.31857/S0869803122030043.
26. Koterov A.N., Tukov A.R., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Average Accumulated Radiation Doses for Global Nuclear Workers: Low Doses, Low Effects, and Comparison with Doses For Medical Radiologists. Biology Bulletin. 2022;49;12:2475–2485. https://doi.org/10.1134/S106235902212007X.
27. Koterov A.N., Ushenkova L.N., Dibirgadzhiev I.G., Waynson A.A., Kalinina M.V., Biryukov A.P. Excess Relative Risk of Cataractogenic Lense Disorders in Nuclear Workers: Systematic Review and Meta-Analysis. Medits. Radiologiya i Radiat. Bezopasnost = Medical Radiology and Radiation Safety. 2023;68;3:21–32 (In Russ.). https://doi.org/10.33266/1024-6177-2023-68-3-21-32.
28. Koterov A.N., Ushenkova L.N., Kalinina M.V., Biryukov A.P. The ‘Healthy Worker Effect’ on Indexes of Total Mortality and Malignant Neoplasms Mortality for Nuclear and Chemical Workers: Meta-Analysis. Medits. Radiologiya i Radiat. Bezopasnost = Medical Radiology and Radiation Safety. 2023;68;4:43–50 (In Russ.). https://doi.org/10.33266/1024-6177-2023-68-4-43-50.
29. IARC 2004. Tobacco Smoke and Involuntary Smoking. Vol. 83. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. France, Lyon, 2004. 1473 p.
30. Webb P, Bain C. Essential Epidemiology. An Introduction for Students and Health Professionals. 2nd Edition. Cambridge etc.: Cambridge University Press, 2011. 445 p.
31. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring Inconsistency in Meta-Analyses. Brit. Med. J. 2003;327;7414:557–560. https://doi.org/10.1136/bmj.327.7414.557.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. Brit. Med. J. 1997;315;7109:629–34. https://doi.org/10.1136/bmj.315.7109.629.
33. Sterne J.A.C., Egger M. Funnel Plots for Detecting Bias in Meta-Analysis: Guidelines on Choice of Axis. J. Clin. Epidemiol. 2001;54;10:1046–1055. https://doi.org/10.1016/s0895-4356(01)00377-8.
34. Kokunin V.A. Statistical Processing of Data from a Small Number of Experiments. Ukr. Biokhim. Zh. = Ukrainian Journal of Biochemistry. 1975;47;6:776–791 (In Russ.).
35. Higgins J.P.T., Li T., Deeks J.J. Chapter 6: Choosing Effect Measures and Computing Estimates of Effect. 6.3 Extracting Estimates of Effect Directly. 6.3.1 Obtaining Standard Errors from Confidence Intervals and P Values: Absolute (Difference) Measures. Cochrane Handbook for Systematic Reviews of Interventions, 2nd Edition. Ed. by J.P.T. Higgins, T. James, J. Chandler, M. Cumpston, T. Li, M.J. Page, V.A. Welch. 2019. https://doi.org/10.1002/9781119536604. https://training.cochrane.org/handbook/current/chapter-06/ (accessed date: 2024/02/02).
36. Lv X., Sun J., Bi Y., Xu M., Lu J., Zhao L., Xu Y. Risk of All-Cause Mortality and Cardiovascular Disease Associated with Secondhand Smoke Exposure: a Systematic Review and Meta-Analysis. Int. J. Cardiol. 2015;199:106–115. https://doi.org/10.1016/j.ijcard.2015.07.011.
37. Boffetta P., Tredaniel J., Greco A. Risk of Childhood Cancer and Adult Lung Cancer after Childhood Exposure to Passive Smoke: a Meta-Analysis. Environ. Health Perspect. 2000;108;1:73–82. https://doi.org/10.1289/ehp.0010873.
38. Wang Y.T., Hu K.R., Zhao J., Ai F.L., Shi Y.L., Wang X.W., et al. The Association Between Exposure to Second-Hand Smoke and Disease in the Chinese population: a Systematic Review and Meta-Analysis. Biomed. Environ Sci. 2023;36;1:24–37. https://doi.org/10.3967/bes2023.003.
39. Kim A.S., Ko H.J., Kwon J.H., Lee J.M. Exposure to Secondhand Smoke and Risk of Cancer in Never Smokers: a Meta-Analysis of Epidemiologic Studies. Int. J. Environ. Res. Public. Health. 2018;15;9;Article E1981:17 p. https://doi.org/10.3390/ijerph15091981.
40. Chuang S.C., Gallo V., Michaud D., Overvad K., Tjonneland A., Clavel-Chapelon F., et al. Exposure to Environmental Tobacco Smoke in Childhood and Incidence of Cancer in Adulthood in Never Smokers in the European Prospective Investigation into Cancer and Nutrition. Cancer Causes Control. 2011;22;3:487–494. https://doi.org/10.1007/s10552-010-9723-2.
41. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to Meta-Analysis. John Wiley & Sons, Ltd, 2009. 421 p.
42. LeVois M.E., Layard M.W. Publication Bias in The Environmental Tobacco Smoke/Coronary Heart Disease Epidemiologic Literature. Regul. Toxicol. Pharmacol. 1995;21;1:184–191. https://doi.org/10.1006/rtph.1995.1023.
43. Wing S., Richardson D.B. Age at Exposure to Ionising Radiation and Cancer Mortality among Hanford Workers: Follow up through 1994. Occup. Environ. Med. 2005;62;7:465–472. https://doi.org/10.1136/oem.2005.019760.
44. Cardis E., Vrijheid M., Blettner M., Gilbert E., Hakama M., Hill C., et al. The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risks. Radiat. Res. 2007;167;4:396–416. https://doi.org/10.1667/RR0553.1.
45. Wakeford R. Nuclear Worker Studies: Promise and Pitfalls. Br. J. Cancer. 2014;110;1:1–3. https://doi.org/10.1038/bjc.2013.713.
46. Daniels R.D., Bertke S.J., Richardson D.B., et al. Examining Temporal Effects on Cancer Risk in the International Nuclear Workers’ Study. Int. J. Cancer. 2017;140;6:1260–1269. https://doi.org/10.1002/ijc.30544.
47. Richardson D.B., Cardis E., Daniels R.D., et al. Risk of Cancer from Occupational Exposure to Ionising Radiation: Retrospective Cohort Study of Workers in France, the United Kingdom, and the United States (INWORKS). Br. Med. J. 2015;351;Articleh5359. https://doi.org/10.1136/bmj.h5359.
48. Azizova T.V., Batistatou E., Grigorieva E.S., McNamee R., Wakeford R., Liu H., et al. An Assessment of Radiation-Associated Risks of Mortality from Circulatory Disease in the Cohorts of Mayak and Sellafield Nuclear Workers. Radiat. Res. 2018;189;4:371–388. https://doi.org/10.1667/RR14468.1.
49. McGeoghegan D., Binks K. The Mortality and Cancer Morbidity Experience of Employees at the Chapelcross Plant of British Nuclear Fuels plc, 1955–95. J. Radiol. Prot. 2001;21;3:221–250. https://doi.org/10.1088/0952-4746/21/3/302.
50. Zablotska L.B., Lane R.S., Frost S.E. Mortality (1950–1999) and Cancer Incidence (1969–1999) of Workers in the Port Hope Cohort Study Exposed to a Unique Combination of Radium, Uranium and γ-Ray Doses. BMJ Open. 2013;3;2;Article e002159:19p. https://doi.org/10.1136/bmjopen-2012-002159.
51. Vrijheid M., Cardis E., Ashmore P., Auvinen A., Bae JM., Engels H., et al. Mortality from Diseases other than Cancer Following Low Doses of Ionizing Radiation: Results from the 15-Country Study of Nuclear Industry Workers. Int. J. Epidemiol. 2007;36;5:1126–1135. https://doi.org/10.1093/ije/dym138.
52. Koterov A.N. From Very Low to Very Large Doses of Radiation: New Data on Ranges Definitions and its Experimental and Epidemiological Basing. Medits. Radiologiya i Radiat. Bezopasnost = Medical Radiology and Radiation Safety. 2013;58;2:5–21 (In Russ.).
53. Koterov AN, Waynson AA. Conjunctural Approach to the Concept of Low Dose Radiation Range with Low Let in Foreign Review Sources: No Changes for 18 Years. Medits. Radiologiya i Radiat. Bezopasnost = Medical Radiology and Radiation Safety. 2022;67;5:33–40. (In Russ.). https://doi.org/10.33266/1024-6177-2022-67-5-33-40.
54. Koterov A.N., Ushenkova L.N., Waynson A.A., Dibirgadzhiev I.G., Biryukov A.P. Excess Relative Risk of Mortality from Disease of the Circulation System after Irradiation. Report 1. Overview of Reviews and Meta-Analysis Declared Effects of Low Doses. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2022;63;1:3–33 (In Russ.). https://doi.org/10.31857/S0869803123010095.
55. Koterov A.N., Ushenkova L.N., Waynson A.A., Dibirgadzhiev I.G., Biryukov A.P. Excess Relative Risk of Mortality from Diseases of the Circulation System after Irradiation: Report 1. Overview of Reviews and Meta-Analysis Declared Effects of Low Doses. Biology Bulletin. 2023;50;12:3155–3183. https://doi.org/10.1134/S1062359023120142.
56. Moher D., Liberati A., Tetzlaff J., Altman D.G. (PRISMA Group). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med. 2009;6;7;Article e1000097:6p. https://doi.org/10.1371/journal.pmed.1000097.
57. Omel’yanovskiy V.V., Avksentyeva M.V., Sura M.V., Khachatryan G.R., Fedyaeva V.K. Guidelines for Conducting a Meta-Analysis. Moscow Publ., 2017. 28 p. (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.